AI Equity - Growth Potential & Arbitrage

An Australian-based Income Loan Fund is offering sophisticated investors the opportunity to acquire discounted equity in a high-growth AI technology company at AUD 8.00 per share, targeting an uplift to AUD 14.00. This short-term arbitrage opportunity provides immediate value and long-term growth potential as the fund rebalances its portfolio.

Key Investment Details
- Discounted Pricing - Shares available at AUD 8.00, targeting AUD 14.00 in the next funding round.
- Offer Size - Up to AUD 3,000,000, with a minimum subscription of AUD 25,000.
- Use of Funds - Provides liquidity for the fund to rebalance its portfolio while maintaining growth potential.
- Institutional Backing - Supported by global investors, with advanced funding discussions in progress.
- AI Platform Overview

The AI platform is a market leader in health diagnostics, leveraging AI technology to deliver fast, affordable, and accurate screening solutions. It has established partnerships with insurers and enterprise platforms, driving adoption and scalability.

- Proven Technology - AI-powered diagnostics with clinical-grade accuracy.
- Enterprise Adoption - Agreements with insurers and technology providers for scalable rollout.
- Revenue Model - SaaS subscriptions and data monetisation ensure recurring income streams.
- Global Growth Potential - Positioned to capture demand for AI healthcare and digital diagnostics.

Offer Summary

- Offeror - Income Loan Fund via segregated trust structure.
- Security - Ordinary shares in the AI platform, held securely in trust.
- Subscription - AUD 25,000 minimum, available in multiples.
- Offer Size - Up to AUD 3,000,000, with no minimum raise.
- Pricing - Shares priced at AUD 8.00, targeting AUD 14.00 in the next funding round.
- Liquidity Event - Provides value uplift potential through planned growth strategies.

Returns & Flexibility
- Immediate Arbitrage Growth - Upside based on discounted pricing.
- Portfolio Liquidity - Allows investors to participate in high-growth AI markets while offering fund liquidity
- Institutional Confidence - Backed by global funding commitments and strong adoption pipelines.

Want to learn more? Contact us today.

Disclaimer: Investors should review the Deed Poll as this investment carries risks. Our firm acts as an independent adviser to the Income Loan Fund, facilitating this offer to rebalance its portfolio.

Munich Partners Capital (Australia)
Level 13/50 Margaret Street, Sydney, NSW 2000
backoffice@munichpartners.com.au

The AI platform is a market leader in health diagnostics, leveraging AI technology to deliver fast, affordable, and accurate screening solutions. It has established partnerships with insurers and enterprise platforms, driving adoption and scalability.

This release was published on openPR.